Toronto - Delayed Quote CAD

Organigram Global Inc. (OGI.TO)

1.3200 -0.0500 (-3.65%)

At close: October 30 at 4:00:00 PM EDT

Chart Range Bar

Loading chart for OGI.TO

Previous Close 1.3700
Open 1.3200
Bid 1.3100 x --
Ask 1.3500 x --
Day's Range 1.3050 - 1.3500
52 Week Range 1.1950 - 3.0900
Volume 122,159
Avg. Volume 137,122
Market Cap (intraday) 190.282M
Beta (5Y Monthly) 1.98
PE Ratio (TTM) 2.20
EPS (TTM) 0.6000
Earnings Date (est.) Dec 15, 2026
Forward Dividend & Yield -- (0.00%)
Ex-Dividend Date --
1y Target Est 2.92

Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, beverages, gummies, and concentrates; and adult use recreational cannabis under the SHRED, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Boxhot, Edison JOLTS, Wola, Rizzlers, DEBUNK, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings and dried flowers to other licensed producers. It sells cannabis products to wholesale and retail channels in the recreational and medical cannabis regimes, as well as through online. Organigram Global Inc. was formerly known as Organigram Holdings Inc. and changed its name to Organigram Global Inc. in March 2025. The company is headquartered in Toronto, Canada.

www.organigram.ca

1,139

Full Time Employees

September 30

Fiscal Year Ends

Healthcare

Sector

Drug Manufacturers - Specialty & Generic

Industry

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

OGI.TO

43.10%

S&P/TSX Composite index (^GSPTSE)

11.78%

1-Year Return

OGI.TO

40.54%

S&P/TSX Composite index (^GSPTSE)

18.03%

3-Year Return

OGI.TO

7.69%

S&P/TSX Composite index (^GSPTSE)

88.90%

5-Year Return

OGI.TO

87.91%

S&P/TSX Composite index (^GSPTSE)

69.32%

Earnings Per Share

gaap GAAP

nongaap Normalized

gaap GAAP

nongaap Normalized

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q3 FY26

Revenue 105.78M

Earnings 105.54M

Profit Margin 99.77%

FY25

FY26

50M

100M

0.0%

50.0%

Analyst Price Targets

1.85

2.92 Average

1.3200 Current

3.50 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

28.02%
Return on Assets (ttm)

-0.60%
Return on Equity (ttm)

17.56%
Revenue (ttm)

309.18M
Net Income Avi to Common (ttm)

86.62M
Diluted EPS (ttm)

0.6000

Balance Sheet and Cash Flow

Total Cash (mrq)

11.67M
Total Debt/Equity (mrq)

5.69%
Levered Free Cash Flow (ttm)

-1.25M

CRON.TO Cronos Group Inc.

4.6200 -2.33%

TLRY.TO Tilray Brands, Inc.

3.5100 -4.62%

LABS.TO MediPharm Labs Corp.

0.0650 0.00%

HITI.V High Tide Inc.

3.6200 -2.95%

CWEB.TO Charlotte's Web Holdings, Inc.

0.3100 -3.12%

U.S. markets open in 29m

Organigram Global Inc. (OGI.TO)

0.76%

-7.04%

-30.89%

-43.10%

-40.54%

-87.91%

12.07%

Organigram Global Inc. Overview Drug Manufacturers - Specialty & Generic / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share

Revenue vs. Earnings

Analyst Insights

Analyst Price Targets

Analyst Recommendations

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch